AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review

 AstraZeneca (AZN) and Daiichi Sankyo have moved a step closer to expanding the U.S. usage of their cancer treatment, Enhertu. The FDA accepted their application to include the drug as a pre-surgery option for patients with HER2-positive stage 2 or 3 breast cancer, alongside other treatments like paclitaxel. Backed by positive results from the DESTINY-Breast11 Phase 3 trial, the FDA has set May 18, 2026, as the target date for a decision that could introduce a new preoperative therapy option.

https://www.gurufocus.com/news/3126893/astrazeneca-azn-and-daiichi-sankyos-enhertu-advances-in-fda-review